title: Weight management in obesity - past and present.
abstract: OBJECTIVE
  To describe the treatment of obesity from ancient times to present day.
  
  
  METHODS
  Articles reporting the development of anti-obesity therapies were identified through a search for 'anti-obesity' AND 'pharmacotherapy' AND 'development' within the title or abstract on PubMed and 'obesity' in ClinicalTrials.gov. Relevant articles and related literature were selected for inclusion.
  
  
  RESULTS
  Stone-age miniature obese female statuettes indicate the existence and cultural significance of obesity as long as 30,000 years ago. Records from Ancient Egyptian and Biblical eras through Greco-Roman to Medieval times indicate that obesity was present throughout the major periods of history, although peoples of previous centuries would probably have experienced overweight and obesity as exceptional rather than normal. Health risks of obesity were noted by the Greek physician Hippocrates (460-377 BCE) when the earliest anti-obesity recommendations on diet, exercise, lifestyle and use of emetics and cathartics were born. These recommendations remained largely unchanged until the early 20th century, when spreading urbanisation, increasingly sedentary jobs and greater availability of processed foods produced a sharp rise in obesity. This led to the need for new, more effective, ways to lose weight, to address comorbidities associated with obesity, and to attain the current cultural ideal of slimness. Drug companies of the 1940s and 1950s produced a series of anti-obesity pharmacotherapies in short succession, based largely on amphetamines. Increased regulation of drug development in the 1960s and new efficacy requirements for weight-loss drugs led to rapid reduction in anti-obesity therapies available by the early 1990s.
  
  
  CONCLUSIONS
  In the last two decades, several new and emerging therapies have been approved or are in development to provide safe, long-term pharmacological agents for the treatment of obesity.
authors.affiliation: The Cheyne Society, Datchworth, UK.
authors.forename: D
authors.initials: D
authors.lastname: Haslam
mesh_terms: D019440:Anti-Obesity Agents / Q000266:history / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D049670:History, 17th Century; D049671:History, 18th Century; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D049690:History, Ancient; D049691:History, Medieval; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000266:history / Q000534:rehabilitation; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents
references.citation: Clin Pharmacol Ther. 1992 May;51(5):586-94
references.pmid: 1587072
references.citation: Int J Obes (Lond). 2014 Jun;38(6):784-93
references.pmid: 23999198
references.citation: Diabetes Obes Metab. 2015 Jun;17(6):566-72
references.pmid: 25732625
references.citation: Biochim Biophys Acta. 2013 Oct;1831(10):1499-508
references.pmid: 23470257
references.citation: Am J Public Health Nations Health. 1934 Oct;24(10):1045-53
references.pmid: 18014064
references.citation: N Engl J Med. 2015 Jul 2;373(1):11-22
references.pmid: 26132939
references.citation: Curr Neuropharmacol. 2012 Mar;10(1):49-52
references.pmid: 22942877
references.citation: BMJ. 2013;346:f1936
references.pmid: 23585064
references.citation: J Pharmacol Exp Ther. 1994 May;269(2):792-8
references.pmid: 7514223
references.citation: Int J Obes (Lond). 2007 Mar;31(3):494-9
references.pmid: 16953261
references.citation: Lancet. 2007 Nov 17;370(9600):1706-13
references.pmid: 18022033
references.citation: Expert Opin Ther Pat. 2013;23(6):725-35
references.pmid: 23607332
references.citation: N Engl J Med. 2010 Sep 2;363(10):905-17
references.pmid: 20818901
references.citation: Can Med Assoc J. 1962 Jul 7;87:29-31
references.pmid: 14463177
references.citation: J Clin Epidemiol. 1998 Apr;51(4):361-4
references.pmid: 9539893
references.citation: BMJ. 2007 Dec 8;335(7631):1194-9
references.pmid: 18006966
references.citation: Nature. 2009 May 14;459(7244):248-52
references.pmid: 19444215
references.citation: Nat Rev Endocrinol. 2015 Aug;11(8):489-501
references.pmid: 26122319
references.citation: Obes Res Clin Pract. 2015 Sep-Oct;9(5):435-47
references.pmid: 25979684
references.citation: World J Surg. 2004 Jun;28(6):631-5
references.pmid: 15366758
references.citation: Lancet. 2009 Jul 4;374(9683):39-47
references.pmid: 19515413
references.citation: Diabetes Obes Metab. 2007 May;9(3):259-75
references.pmid: 17391151
references.citation: Clin Pharmacol Ther. 1992 May;51(5):642-6
references.pmid: 1587079
references.citation: Diabetes Care. 2009 Jan;32(1):84-90
references.pmid: 18931095
references.citation: Diabetologia. 2009 Oct;52(10):2046-55
references.pmid: 19688338
references.citation: Diabetes Care. 2004 Jan;27(1):155-61
references.pmid: 14693982
references.citation: Obesity (Silver Spring). 2011 Jan;19(1):110-20
references.pmid: 20559296
references.citation: Circ Cardiovasc Imaging. 2013 Jul;6(4):560-7
references.pmid: 23661689
references.citation: Horm Metab Res. 2008 Aug;40(8):539-43
references.pmid: 18500680
references.citation: N Engl J Med. 2010 Jul 15;363(3):245-56
references.pmid: 20647200
references.citation: Can Med Assoc J. 1957 Jan 15;76(2):117-20
references.pmid: 13383418
references.citation: Adv Ther. 2006 Nov-Dec;23(6):1016-29
references.pmid: 17276969
references.citation: Clin Psychopharmacol Neurosci. 2013 Apr;11(1):7-12
references.pmid: 23678348
references.citation: J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77
references.pmid: 21795446
references.citation: Am J Clin Nutr. 2012 Feb;95(2):297-308
references.pmid: 22158731
references.citation: Int J Obes (Lond). 2014 Feb;38(2):292-8
references.pmid: 23736363
references.citation: Lancet. 2010 Jul 10;376(9735):85-6
references.pmid: 20629209
references.citation: N Engl J Med. 1997 Aug 28;337(9):581-8
references.pmid: 9271479
references.citation: Diabetes Obes Metab. 2010 Oct;12(10):876-82
references.pmid: 20920040
references.citation: Obesity (Silver Spring). 2012 Feb;20(2):330-42
references.pmid: 22051941
references.citation: Am J Public Health. 2008 Jun;98(6):974-85
references.pmid: 18445805
references.citation: Yonsei Med J. 2006 Oct 31;47(5):614-25
references.pmid: 17066505
references.citation: Diabetes Obes Metab. 2012 Jun;14(6):523-30
references.pmid: 22192338
references.citation: J Psychopharmacol. 2010 Jan;24(1):99-109
references.pmid: 18755818
references.citation: Obesity (Silver Spring). 2010 Jan;18(1):108-15
references.pmid: 19461584
references.citation: Ann Intern Med. 2005 Sep 6;143(5):380-5
references.pmid: 16144896
references.citation: Int J Obes Relat Metab Disord. 2002 Feb;26(2):262-73
references.pmid: 11850760
references.citation: J Clin Psychiatry. 2007 Aug;68(8):1226-9
references.pmid: 17854247
references.citation: Lancet. 2010 Apr 24;375(9724):1447-56
references.pmid: 20417856
references.citation: World J Surg. 2004 May;28(5):513-7
references.pmid: 15107945
references.citation: Nature. 1996 Jan 4;379(6560):69-72
references.pmid: 8538742
references.citation: Diabetes Care. 2003 Nov;26(11):3172-8
references.pmid: 14578257
references.citation: Obesity (Silver Spring). 2013 Nov;21(11):2163-71
references.pmid: 24136928
references.citation: Lancet. 2009 Feb 7;373(9662):473-81
references.pmid: 18819705
references.citation: Psychosomatics. 1977;18(1):28-33
references.pmid: 850721
references.citation: Endocrine. 2006 Feb;29(1):49-60
references.pmid: 16622292
references.citation: Diabet Med. 2009 Mar;26(3):268-78
references.pmid: 19317822
references.citation: Arch Intern Med. 1983 Dec;143(12):2301-3
references.pmid: 6360064
references.citation: N Engl J Med. 2012 Oct 25;367(17):1577-9
references.pmid: 23050510
references.citation: J Psychopharmacol. 2013 Jun;27(6):479-96
references.pmid: 23539642
references.citation: Lancet. 2011 Apr 16;377(9774):1341-52
references.pmid: 21481449
references.citation: Drug Test Anal. 2014 Jan-Feb;6(1-2):24-30
references.pmid: 24006213
references.citation: Diabetes Care. 2009 Jul;32(7):1224-30
references.pmid: 19289857